tgfβ1

TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.

Disitertide acetate (P144 acetate) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide acetate is also a PI3K inhibitor and an apoptosis inducer.

AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.

Tubastatin inhibits TGF-β1-induced phosphorylation of S6K, HIF-1α expression and VEG F expression.Tubastatin inhibits TGF-β1-induced inhibition of LC3B-II, a marker of autophagosome formation.

Asiaticoside (Emdecassol) (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.

RU-301 is a novel pan-tam inhibitor

Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 and can be used to study focal segmental glomerulosclerosis and cancer in adults.

TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1].

TGFβ1-IN-3, a diarylhydrazone derivative, inhibits fibroblast activation and proliferation, positioning it as a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).

TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase (IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively ).

TGF-β1/Smad3-IN-1 (Compound 5aa) is an orally administrable dual inhibitor of TGF-β1/Smad3 with anti-fibrotic activity and can be used for the study of idiopathic pulmonary fibrosis (IPF).

TGF-β1/Smad-IN-1 (compound C9) is a potent inhibitor of TGF-β1/Smad. It effectively suppresses the expression of fibrosis markers (α-SMA and COL1A1) induced by TGF-β1 and exhibits antifibrotic properties. This compound holds potential for research in liver fibrosis.

TGF-β2-IN-1 is a selective inhibitor of TGF-β2. It exhibits potent antiproliferative effects on HCT-116, Caco-2, and HT-29 cells, with IC50 values of 6.84, 10.21, and 9.47 μM, respectively. TGF-β2-IN-1 inhibits TGF-β2 signaling in a dose-dependent manner by suppressing receptor and cytokine expression. This compound is useful for colorectal cancer research.

TGFβ-IN-1 is an antitumor growth and metastasis agent that functions by inhibiting the transforming growth factor β (TGFβ) signaling pathway.

TGFβR-IN-1 is a long-acting, tumor-activated proagent for a TGFβR inhibitor.

pm26TGF-β1 peptide, mimicking a portion of the human TGF-β1 molecule, demonstrates a high affinity for the TGF-β1 receptor. It exhibits potent anti-inflammatory properties without inducing neutrophils' chemoattraction [1] [2].

pm26TGF-β1 TFA peptide is a synthetic peptide that emulates a segment of the human TGF-β1 molecule, demonstrating high affinity for the TGF-β1 receptor. It possesses potent anti-inflammatory capabilities while lacking the ability to attract neutrophils [1] [2].

Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an IgG antibody inhibitor targeting TGF-β in multiple species including mouse, human, rabbit, monkey, hamster, dog, and cow. For information on the isotype control, refer to Mouse IgG1 kappa, Isotype Control.

CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 μM, disrupting the TGF-β-TβR-I-TβR-II signaling complex and inhibiting cell migration.

TrxR-IN-5 (compound 4f) is an effective inhibitor of thioredoxin reductase (TrxR) with an IC₅₀ of 0.16 μM. TrxR-IN-5 increases reactive oxygen species (ROS) levels, reverses TGFβ1-induced epithelial-mesenchymal transition, and exhibits anti-proliferative and anti-metastatic effects against human breast cancer cells.

DL-Cystine is a cysteine derivative that inhibits endothelial cell proliferation by regulating TGFβ1. It is also a GPR inhibitor and nAChR agonist and can be used in biochemical experiments.

Disitertide (P144) TFA is a peptide-based inhibitor of transforming growth factor-beta 1 (TGF-β1), designed to prevent its interaction with the receptor, while also functioning as a PI3K inhibitor and promoting apoptosis [1] [2] [3] [4] [5].

Disitertide (P144) diammonium, a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor, is specifically engineered to prevent its receptor interaction. Additionally, it serves as a PI3K inhibitor and induces apoptosis, as evidenced by references [1] [2] [3] [4] [5].

Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).